Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

janssen-cilag a/s - fentanyl - depotplastre - 100 mikrogram/time

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

janssen-cilag a/s - fentanyl - depotplastre - 12 mikrogram/time

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

janssen-cilag a/s - fentanyl - depotplastre - 25 mikrogram/time

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

janssen-cilag a/s - fentanyl - depotplastre - 50 mikrogram/time

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

janssen-cilag a/s - fentanyl - depotplastre - 75 mikrogram/time

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

v.m.d. n.v. - butorphanoltartrat - injektionsvæske, opløsning - 10 mg/ml - hest, hund

Den Europæiske Union - dansk - EMA (European Medicines Agency)

molmed spa - allogen t celler genetisk modificeret med en retroviral vektor kodning for en afkortet form af menneskelige lav affinitet nerve vækstfaktor receptor (Δlngfr) og herpes simplex virus thymidine kinase (hsv-tk mut2) - hematopoietic stem cell transplantation; graft vs host disease - antineoplastiske midler - zalmoxis er indiceret som supplerende behandling ved haploidentisk hæmatopoietisk stamcelle-transplantation (hsct) hos voksne patienter med højrisiko hæmatologiske maligniteter.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

centauri biotech sl - allogen enhovede fedtvæv udvundet af mesenchymal stem cells - heste - til behandling af slidgigt hos voksne ikke-fødevareproducerende heste.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

adienne s.r.l. s.u. - melphalan hydrochloride - multiple myeloma; hodgkin disease; lymphoma, non-hodgkin; precursor cell lymphoblastic leukemia-lymphoma; leukemia, myeloid, acute; neuroblastoma; ovarian neoplasms; hematopoietic stem cell transplantation - antineoplastiske midler - high-dose of phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (hodgkin, non-hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma. phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (ric) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-hsct) in malignant haematological diseases in adults. phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:myeloablative conditioning (mac) treatment in case of malignant haematological diseasesric treatment in case of non-malignant haematological diseases.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

esteve pharmaceuticals gmbh - thiotepa - hematopoietic stem cell transplantation; neoplasms - antineoplastiske midler - thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients. thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients.